Sleep Quality & Recovery — Peptide Research Overview

Relevant Compounds

• Sermorelin — GHRH analog that stimulates natural pulsatile GH release, particularly during slow-wave sleep.
• DSIP — Delta Sleep-Inducing Peptide; a nonapeptide that modulates NREM sleep architecture and has anxiolytic properties.
• MK-677 — Oral ghrelin mimetic (ibutamoren) that significantly increases GH and IGF-1 levels. Studies show increased REM and slow-wave sleep.
• CJC-1295 / Ipamorelin — GHRH analog combined with selective GHRP. The combination amplifies pulsatile GH release at night without cortisol/prolactin elevation.

What the Research Shows

Sermorelin

[Human Trial] Sermorelin has been through Phase 3 trials (FDA-approved for pediatric GH deficiency; off-label in adults). Clinical use demonstrates increased IGF-1 and improved sleep quality scores in adults with GH deficiency. Bedtime dosing takes advantage of the natural GH pulse that occurs 1–2 hours after sleep onset.

DSIP

[Animal Study / Preliminary Human] DSIP was isolated from rabbit brain in 1977 and found to induce delta (slow-wave) sleep in multiple species. Small human studies show decreased sleep latency, increased slow-wave sleep percentage, and reduced cortisol reactivity. Evidence quality is limited by study size.

MK-677

[Human Trial] A randomized crossover trial (Copinschi et al., 1997) demonstrated that MK-677 increased slow-wave sleep by ~20% and REM sleep duration in healthy adults. Subsequent trials in elderly subjects confirmed improved sleep quality alongside increased IGF-1. Oral bioavailability makes compliance high.

CJC-1295 / Ipamorelin

[Animal Study / Preliminary Human] The combination of CJC-1295 (GHRH analog) with Ipamorelin (selective GHRP) produces additive GH release without significant elevation of cortisol or prolactin — a cleaner GH pulse than older GHRPs like GHRP-2 or GHRP-6. Improved sleep quality is commonly reported in clinical research use.

Evidence Summary